Biologic therapy demonstrates improved outcomes in chronic rhinosinusitis with nasal polyps, suggesting a shift to personalized treatments.
Biologic therapy has shifted CRSwNP management towards a more personalized, mechanism-based approach. Upstream-targeted treatments represent an important step forward, particularly for patients with refractory or mixed disease. Future research should focus on biomarker-guided therapy and long-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Zahedi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: